Prognostic relevance of cancer-associated fibroblasts in human cancer

Seminars in Cancer Biology

Volumn 25, Issue , 2014, Pages 61-68

  Paulsson, Janna ^a   Micke, Patrick ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; CAF; Non small cell lung cancer; Prognostic CAF markers; Tumor stroma

Indexed keywords

CAVEOLIN 1; GELATINASE A; MATRIX METALLOPROTEINASE; OSTEONECTIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PODOPLANIN; SCLEROPROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXF1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR MARKER;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL SURVIVAL; DISEASE MARKER; FIBROBLAST; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; REVIEW; ANIMAL; BREAST NEOPLASMS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84897483751     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.02.006     Document Type: Review

References (102)

1. Micke P., Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005, 9(6):1217-1233.
2. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010, 316(8):1324-1331.
3. Gahr S., et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer 2013, 109(7):1821-1828.
4. Curigliano G., et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27(34):5693-5699.
5. Fridman W.H., et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011, 71(17):5601-5605.
6. Suzuki K., et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011, 17(16):5247-5256.
7. Schmidt M., et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012, 18(9):2695-2703.
8. Lohr M., et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013, 333(2):222-228.
9. Galon J., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014, 232(2):199-209.
10. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117(17):3889-3899.
11. Magennis D.P. Angiogenesis: a new prognostic marker for breast cancer. Br J Biomed Sci 1998, 55(3):214-220.
12. Kirkwood J.M., et al. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62(5):309-335.
13. Bellou S., et al. Anti-angiogenesis in cancer therapy: hercules and hydra. Cancer Lett 2013, 338(2):219-228.
14. Micke P., Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl. 2):S163-S175.
15. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19(11):1423-1437.
16. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr Opin Genet Dev 2009, 19(1):67-73.
17. Strell C., Rundqvist H., Ostman A. Fibroblasts - a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci 2012, 117(2):187-195.
18. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5(15):1597-1601.
19. Shimosato Y., et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol 1980, 4(4):365-373.
20. Demarchi L.M., et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol 2000, 13(5):511-520.
21. Takise A., et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2cm in diameter. Cancer 1988, 61(10):2083-2088.
22. Lee T.K., et al. Morphometric and morphologic evaluations in stage III non-small cell lung cancers, prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer 1989, 63(2):309-316.
23. Takahashi Y., et al. Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients. J Thorac Oncol 2011, 6(9):1460-1467.
24. Soderdahl G., et al. Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. Int J Cancer 1988, 41(4):636-641.
25. Kawai T., Hiroi S., Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997, 77(5):431-436.
26. Boldrini L., et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000, 83(4):480-486.
27. Saji H., et al. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg 2003, 9(5):295-300.
28. Hasegawa Y., et al. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 2001, 91(5):964-971.
29. Al-Saad S., et al. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008, 99(9):1476-1483.
30. Donnem T., et al. Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008, 3(9):963-970.
31. Donnem T., et al. Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 2010, 21(2):223-231.
32. Edlund K., et al. CD99 is a novel prognostic stromal marker in non-small cell lung cancer. Int J Cancer 2012, 131(10):2264-2273.
33. Liu R., et al. Fibroblast activation protein: a potential therapeutic target in cancer. Cancer Biol Ther 2012, 13(3):123-129.
34. Liao Y., et al. Clinical implications of fibroblast activation protein-alpha in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol 2013, 139(9):1523-1528.
35. Ito M., et al. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest 2012, 142(1):151-158.
36. Ono S., et al. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. Chest 2013, 143(4):963-970.
37. Jodele S., et al. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006, 25(1):35-43.
38. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99(2):157-166.
39. Leinonen T., et al. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol 2008, 23(6):693-700.
40. Ishikawa S., et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res 2004, 10(19):6579-6585.
41. Leinonen T., et al. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006, 51(3):313-321.
42. Chlenski A., et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 2006, 118(2):310-316.
43. Koukourakis M.I., et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003, 63(17):5376-5380.
44. Huang Y., et al. SPARC expression and prognostic value in non-small cell lung cancer. Chin J Cancer 2012, 31(11):541-548.
45. Saito R.A., et al. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res 2010, 70(7):2644-2654.
46. Micke P., et al. Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. Lab Invest 2006, 86(2):202-211.
47. Chang H.Y., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2(2):pE7.
48. Navab R., et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011, 108(17):7160-7165.
49. Patani N., Martin L.A., Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013, 133(1):1-13.
50. de Kruijf E.M., et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat 2011, 125(3):687-696.
51. Dekker T.J., et al. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 2013, 139(2):371-379.
52. Moorman A.M., et al. The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol 2012, 38(4):307-313.
53. Beck A.H., et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med 2011, 3(108):108ra113.
54. Surowiak P., et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007, 27(4C):2917-2924.
55. Paulsson J., et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175(1):334-341.
56. Ariga N., et al. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001, 95(1):67-72.
57. Schoppmann S.F., et al. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 2012, 134(1):237-244.
58. Pula B., et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology 2011, 59(6):1249-1260.
59. Folgueira M.A., et al. Markers of breast cancer stromal fibroblasts in the primary tumour site associated with lymph node metastasis: a systematic review including our case series. Biosci Rep 2013, 33(6).
60. Sugimoto H., et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006, 5(12):1640-1646.
61. Busch S., et al. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 2013, [Epub ahead of print]. 10.1038/onc.2013.527.
62. O'Toole S.A., et al. Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011, 71(11):4002-4014.
63. Niemiec J., et al. Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. Clin Breast Cancer 2013, 13(2):119-128.
64. Gonzalez L.O., et al. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. Hum Pathol 2009, 40(9):1224-1233.
65. Auvinen P., et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000, 156(2):529-536.
66. Auvinen P., et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 2013, 132(3):531-539.
67. Ioachim E., et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38(18):2362-2370.
68. Goetz J.G., et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146(1):148-163.
69. Simpkins S.A., et al. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 2012, 227(4):490-498.
70. Qian N., et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 2011, 102(8):1590-1596.
71. DeFilippis R.A., et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov 2012, 2(9):826-839.
72. Chang H.Y., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102(10):3738-3743.
73. Finak G., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14(5):518-527.
74. Planche A., et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS ONE 2011, 6(5):e18640.
75. Bergamaschi A., et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008, 214(3):357-367.
76. Frings O., et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am J Pathol 2013, 182(6):2037-2047.
77. Guo X., et al. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer. Breast Cancer Res 2013, 15(6):R117.
78. Beck A.H., et al. The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 2008, 88(6):591-601.
79. Roman-Perez E., et al. Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res 2012, 14(2):R51.
80. Desmedt C., et al. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. Clin Cancer Res 2012, 18(4):1004-1014.
81. Vargas A.C., et al. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Breast Cancer Res Treat 2012, 135(1):153-165.
82. Ma X.J., et al. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11(1):R7.
83. Sharma M., et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2010, 123(2):397-404.
84. Shekhar M.P., et al. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007, 170(5):1546-1560.
85. Pontiggia O., et al. The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Res Treat 2012, 133(2):459-471.
86. Martinez-Outschoorn U.E., et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011, 12(10):924-938.
87. Farmer P., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15(1):68-74.
88. Busch S., et al. Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. PLoS ONE 2012, 7(9):e45669.
89. Huijbers A., et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013, 24(1):179-185.
90. Wang K., et al. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 2012, 7(9):1457-1461.
91. Labiche A., et al. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int J Gynecol Cancer 2010, 20(1):28-33.
92. Pula B., et al. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. Int J Oncol 2013, 42(6):1849-1857.
93. Leong A.S. Pitfalls in diagnostic immunohistology. Adv Anat Pathol 2004, 11(2):86-93.
94. Ilyas M., et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology 2013, 62(6):827-839.
95. Fetsch P.A., Abati A. The clinical immunohistochemistry laboratory: regulations and troubleshooting guidelines. Methods Mol Biol 2010, 588:399-412.
96. Altman D.G., Riley R.D. Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2005, 2(9):466-472.
97. Metze K. Pitfalls in the assessment of prognostic factors. Lancet Oncol 2011, 12(12):1095-1096.
98. Zhu C.Q., et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006, 59(8):790-800.
99. Chen J.L., et al. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res 2013, 19(18):5127-5135.
100. Ein-Dor L., et al. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics 2005, 21(2):171-178.
101. Boutros P.C., et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA 2009, 106(8):2824-2828.
102. Gokmen-Polar Y., Badve S. Molecular profiling assays in breast cancer: are we ready for prime time?. Oncology (Williston Park) 2012, 26(4):350-357. 361.